Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

icipated global demand for Myozyme. Product supply in 2009 is expected to be particularly tight until the Belgium plant is approved.

Genzyme's other treatments for lysosomal storage disorders also continue to experience strong, double-digit growth. Second-quarter Cerezyme(R) (imiglucerase for injection) sales rose 13 percent to $319.4 million, compared with $283.0 million in the previous second quarter. Sales of Fabrazyme(R) (agalsidase beta) grew 21 percent, rising to $126.6 million from $104.3 million. Sales of Aldurazyme(R) (laronidase) increased 33 percent to $38.8 million, compared with $29.1 million in the second quarter last year when the product's sales were recorded under the joint venture with BioMarin Pharmaceutical Inc.

The company also reported preliminary results from a Phase 2 trial of its investigational oral therapy for Gaucher disease Genz-112638. The results were consistent with those observed for patients beginning enzyme replacement therapy, and they highlight the potential of this compound to provide a convenient treatment alternative for patients and a broader range of treatment options for physicians. Genzyme is developing protocols for two Phase 3 trials that it expects to initiate early next year.

Sales of Thyrogen(R) (thyrotropin alfa for injection) remained strong, increasing 34 percent to $39.4 million from $29.5 million. The use of Thyrogen in ablation procedures is contributing to the product's growth in the United States, while its growth in Europe is being driven by increasing diagnosis of thyroid cancer and its international adoption is being driven by expansion into new geographic markets.

Within the Renal business, sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and Renvela grew 16 percent to $168.6 million from $144.9 million in the second quarter last year. Genzyme launched Renvela in the United States in March, and the product is now included in more than 85 percent of health plan f
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Oct. 10 Twenty of Britain,s most,innovative technology ... at the fifth annual SETsquared Partnership Showcase 2008. ... George Street, London, from 8am on,Thursday, October 16th, ... information technology, engineering and biotechnology., Six companies ...
... 10 Takeda Pharmaceutical Company,Limited ("Takeda") today announced ... wholly owned United States (U.S.) subsidiary,received notification that ... be able to complete its review of the ... User Fee Act (PDUFA) date of October 27,2008., ...
... 9 Pairing traditional quality,tools with innovations ... organizations reduce waste, meet customer expectations and ... Process Improvement Leaders,Produce Profits in Recessions, the ... Practices, LLC,s GLOBAL BENCHMARKING COUNCIL,executives from leading ...
Cached Biology Technology:Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 2Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 3FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes 2Six Sigma and Social Media: Tools for Reducing Costs, Improving Processes 2
(Date:4/18/2014)... world population predicted to reach 9 billion by ... that considers human-altered landscapes such as farmland, according ... habitat that supports it might be an increasingly ... three-quarters of the land surface is directly affected ... human-caused impacts such as climate change. But what ...
(Date:4/18/2014)... R.I. [Brown University] Asteroid and comet impacts can ... on regional or even global scales. But new research ... the signatures of ancient life at the time of ... geologist Pete Schultz has found fragments of leaves and ... several ancient impacts in Argentina. The material could provide ...
(Date:4/17/2014)... infection , Respiratory syncytial virus (RSV) is ... generating life-threating illness in very young and elderly ... RSV enters host cells through the fusion protein ... Small interfering peptides that prevent bundle formation limit ... highly susceptible to degradation. In this issue of ...
Breaking Biology News(10 mins):Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... have discovered that the shape of a protein ... invade the human bloodstream. This,finding, published Dec. 16 ... a vaccine that is significantly more effective at,protecting ... the shape of a large, paddle-like molecule that,Streptococcus ...
... Dartmouth Medical School geneticists have found links in the ... avenues for studying and targeting a process vital to ... The work, reported in the February 17 issue of ... plant, in prompting worm cells to self destruct. These ...
... Two compounds that zero in on cancer cells spreading ... someday give doctors a whole new weapon in the ... College of Cornell University researchers. , The compounds, called ... metastatic breast cancer cells in mice, and are the ...
Cached Biology News:New comparative toxicogenomics database 2New comparative toxicogenomics database 3Critical role in programmed cell death identified 2Critical role in programmed cell death identified 3First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers 2First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers 3